Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grants from
Lilly and Novartis Pharmaceuticals Corporation
Description:
Ankylosing spondylitis (AS) is an immune-mediated chronic
inflammatory disease that typically affects the sacroiliac (SI)
joints. Patients with AS suffer from debilitating pain and joint
fusion that severely limits their mobility and functional capacity.
It is estimated that AS affects approximately 1.6 million people in
the US. Due to an aging population, declining number of
rheumatologists, and limited access to care, care for patients with
AS is suboptimal and costly. Fortunately for patients with this
disease, recent advances in pathogenesis have led to an increased
understanding of the disease, which has subsequently led to the
development of novel targeted agents shown to slow its progression,
including options targeting IL-17/IL-23 pathways.
Upon completion of this
activity, participants will be able to:
-
Assess the burden of ankylosing
spondylitis and the role of managed care professionals in the
management of ankylosing spondylitis
-
Analyze efficacy and safety profiles
of IL-17 and IL-23 inhibitors for ankylosing spondylitis
-
Discuss the managed care
considerations of IL-17 and IL-23 inhibitors by exploring where
these agents fit in the current ankylosing spondylitis
management paradigm
-
Identify co-productive
payer-provider strategies to ensure appropriate and timely
access to IL-17 and IL-23 inhibitors for patients with
ankylosing spondylitis
Faculty: |
Gary Owens, MD
President
Gary Owens Associates |
Disclosure:
|
Dr.
Owens serves as a consultant for Eli Lilly and Roche.
His presentation has been peer reviewed for any bias. |
|
Planning Committee:
Bill Williams,
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
to disclose.
Will Williams has no relevant financial relationships to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
nursing credit.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This presentation is supported by
educational grants from
Lilly and Novartis Pharmaceuticals Corporation
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |